Clinical Trials
367
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (255 trials with phase data)• Click on a phase to view related trials
Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma
- Conditions
- Kaposiform Hemangioendothelioma
- Interventions
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT07131644
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer
- Conditions
- ER+HER2- Breast Cancer
- Interventions
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT07109284
Patient-reported Outcomes (PRO) and Treatment Outcomes of Chinese Patients With MSS-type Advanced Colorectal Cancer Who Received the Zidovudine Combination Regimen in the Real World
- Conditions
- Colorectal Cancer
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT07105631
- Locations
- 🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
- Conditions
- HCC - Hepatocellular CarcinomaMelanomaPancreatic Ductal AdenocarcinomaCholangiocarcinomaHNSCCEndometrial CancerTesticular CancerNSCLC (Non-small Cell Lung Cancer)
- Interventions
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT07106827
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Interventions
- Drug: LICSBR
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT07101679
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 73
- Next
News
Neoadjuvant Immunochemotherapy Shows Promising Results in Locally Advanced Oral Squamous Cell Carcinoma
Neoadjuvant immunochemotherapy with camrelizumab plus nab-paclitaxel and cisplatin demonstrated a favorable pathological response in patients with locally advanced oral squamous cell carcinoma, achieving a 69% major pathological response rate and 41.4% pathological complete response rate.
ICG-HSA Complex Enhances Fluorescence Imaging in Laparoscopic Liver Resection: A Randomized Controlled Trial
A prospective, double-blind, randomized controlled trial is underway to evaluate a novel indocyanine green–human serum albumin (ICG-HSA) complex for fluorescence-guided laparoscopic anatomical liver resection (LALR).
Secukinumab and Adalimumab Show Distinct Benefits in Psoriatic Arthritis Treatment
A recent study comparing secukinumab and adalimumab for psoriatic arthritis (PsA) found both effective, but with distinct advantages.